Blog

The Concerning Rise of Youth Vaping and What States Can Do to Help

Vaping is causing serious lung disease in many teens. Yet, youth vaping continues to rise at an alarming rate. State policies can help curb youth vaping. As part of our 2019 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR), we look at the rise of vaping among our youth and what states can do to reduce rates.

AAFA Releases 2019 State Honor Roll Report in Advance of Asthma Peak Week

Schools provide valuable education to students. But the very resource that is supposed to benefit our children can actually be a cause of asthma symptoms and allergic reactions. Some states have policies in place that protect children with asthma and allergies. These 15 states made our 2019 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR). See how your state ranks.

AAFA Meets With DOT to Advocate for Equal Rights for People With Asthma and Allergies on Planes

The Asthma and Allergy Foundation of America (AAFA) met with the Office of the General Counsel of the U.S. Department of Transportation (DOT). We spoke with members of their Office of Aviation Enforcement and Proceedings and Consumer Protection Division on behalf of people with asthma and allergies. We shared how critical it is that people with asthma and allergies who have to be on planes with emotional support animals have equal rights.

Be Part of a Project to Shape New Eczema Treatments

AAFA has joined with four other nonprofit organizations that serve people with eczema to launch “More Than Skin Deep.” This project will inform and shape the development of treatments for eczema. A main part the project is a patient-focused drug development (PFDD) meeting on Sept. 23, 2019, in Washington, D.C.

Dupixent® Shows Positive Results in Phase 3 of Trial for Ages 6 to 11 With Severe Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.

Managing Asthma in St. Louis: It's Scary Not to Be Able to Breathe

Growing up, Jerica Gordon’s sister had asthma, but she does not remember her having any asthma attacks. “So when my son was having trouble breathing, I thought it was just congestion or something. There was no wheezing that I remember hearing,” she shared. In November 2016, Jerica took her son Jonathan Robinson, Jr., then age 5, to the emergency room.

Post
×
×
×
×